Received Approval from USFDA - Gland Pharma Ltd

Code BSE: 543245 NSE:

Gland Pharma Receives Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) Gland Pharma Ltd has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Olopatadine hydrochloride Ophthalmic Solution USP, 0.7% (OTC) The Product is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon)